Revenue and Income - For the three months ended September 30, 2025, real property rental revenue was $350,099, an increase of $4,940 or 1.4% compared to $345,159 for the same period in 2024[264]. - For the nine months ended September 30, 2025, real property rental revenue was $1,050,305, an increase of $62,671 or 6.3% compared to $987,634 for the same period in 2024[264]. - Real property operating income for the three months ended September 30, 2025 was $115,733, an increase of $16,102 or 16.2% compared to $99,631 for the same period in 2024[268]. - Real property operating income for the nine months ended September 30, 2025 was $284,472, an increase of $90,980 or 47.0% compared to $193,492 for the same period in 2024[268]. - For the nine months ended September 30, 2025, the company reported income from Lab Services MSO of $392,677, which included its share of net income and amortization of identifiable intangible assets[270]. Expenses and Losses - The company incurred a working capital deficit of approximately $11,515,000 at September 30, 2025, with recurring net losses of approximately $16,195,000 for the nine months ended September 30, 2025[253]. - The company generated negative cash flow from operating activities of approximately $4,389,000 for the nine months ended September 30, 2025[253]. - For the three months ended September 30, 2025, advertising and marketing expenses increased by $104,287, or 72.1%, compared to the same period in 2024, while for the nine months, the increase was $390,329, or 154.7%[273]. - Professional fees for the three months ended September 30, 2025, rose by $945,150, or 311.6%, primarily due to increased consulting and legal service fees related to a potential merger with YOOV Group[275]. - Compensation and related benefits decreased by $112,976, or 32.9%, for the three months ended September 30, 2025, and by $159,333, or 15.1%, for the nine months, mainly due to reduced compensation for the executive officer[275]. - Miscellaneous taxes increased by $31,600, or 263.3%, for the three months ended September 30, 2025, primarily due to an increase in Delaware state franchise tax[275]. - Loss from operations for the three months ended September 30, 2025, was $76,193, a decrease of $1,193,768, or 94.0%, compared to the same period in 2024[277]. - Net loss for the three months ended September 30, 2025, was $254,268, a decrease of $1,424,932, or 84.9%, compared to the same period in 2024[282]. - The net loss attributable to common shareholders for the nine months ended September 30, 2025, was $16,032,504, or $6.10 per share, representing an increase of $10,853,765, or 209.6%[284]. - Comprehensive loss for the three months ended September 30, 2025, was $253,997, compared to $1,676,157 for the same period in 2024[286]. Cash Flow and Capital - As of September 30, 2025, the company's cash balance was approximately $334,000, a decrease from $2,856,000 on December 31, 2024[288]. - The working capital deficit increased by $868,585 to $11,514,642 at September 30, 2025, compared to $10,646,057 at December 31, 2024, primarily due to a decrease in cash and increases in accrued liabilities[290]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $4,388,557, reflecting a consolidated net loss of approximately $16,195,000[292]. - Net cash flow provided by investing activities was $752,635 for the nine months ended September 30, 2025, compared to a net cash flow used of $100,000 for the same period in 2024[295]. - Net cash flow provided by financing activities was $1,112,871 for the nine months ended September 30, 2025, down from $4,726,942 in the same period of 2024[296]. - The company expects cash used in operating activities to increase in the next 12 months due to new product development and increased marketing efforts[294]. - The company estimates that its available cash will be insufficient to meet its cash requirements under current operating expectations, necessitating significant additional capital[298]. Operational Changes and Future Outlook - The company suspended all research and development efforts related to cellular therapy to focus on product commercialization[251]. - The KetoAir breathalyzer device is registered with the U.S. FDA as a Class I medical device and is marketed for the diabetes and obesity markets[244][247]. - The company sold its 40% equity interest in Lab Services MSO on February 26, 2025, resulting in no income from this investment for the three months ended September 30, 2025[269]. - The company faces substantial doubt about its ability to continue as a going concern, dependent on raising additional capital and generating sufficient revenues[287]. - The unrealized foreign currency translation gain for the nine months ended September 30, 2025, was approximately $700, compared to $2,800 for the same period in 2024[299]. - The company has ceased all operations in China since 2022, limiting exposure to foreign currency exchange rate fluctuations[299]. - The increase in working capital requirements is attributed to financing current business operations and capital for acquisitions[301].

Core Viewpoint - Avalon GloboCare Corp. is launching the KetoAir™ breathalyzer device in the UK, expanding its market presence following its U.S. launch, targeting individuals on ketogenic diets for health management [1][3]. Product Overview - KetoAir™ is a handheld breathalyzer that measures breath acetone concentration (BrAce), indicating fat metabolism and ketosis, and is registered as a Class I medical device with the U.S. FDA [2][4]. - The device is designed for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, utilizing advanced nano-sensor technology for real-time metabolic insights [2][3]. Market Strategy - The launch in the UK is seen as a strategic move to capitalize on the growing adoption of ketogenic and low-carb diets, positioning KetoAir™ as a tool to help individuals achieve their health and wellness goals [3]. - The product will be available for purchase starting September 1, 2025, through the dedicated website [1][3]. Company Background - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, with plans to explore additional diagnostic uses for the breathalyzer technology [4].

Revenue and Income - Real property rental revenue for Q2 2025 was $350,406, an increase of $22,519 or 6.9% compared to Q2 2024[263] - Real property operating income for Q2 2025 was $99,329, an increase of $56,930 or 134.3% compared to Q2 2024[267] - For the six months ended June 30, 2025, real property rental revenue was $700,206, up $57,731 or 9.0% from the same period in 2024[263] Expenses and Losses - Real property operating expenses for Q2 2025 decreased to $251,077, down $34,411 or 12.1% from Q2 2024[265] - Loss from operations for the three months ended June 30, 2025, amounted to $3,887,987, representing an increase of $2,383,624, or 158.4%, compared to the same period in 2024[274] - Other expense, net, totaled $9,570,611 for the three months ended June 30, 2025, representing an increase of $8,942,948, or 1,424.8%, primarily due to increased third-party interest expense and loss on extinguishment of debt[276] - Net loss for the three months ended June 30, 2025, was $13,458,598, an increase of $11,326,572, or 531.3%, compared to the same period in 2024[279] - The net loss attributable to common shareholders for the three months ended June 30, 2025, was $13,458,598, or $6.22 per share, compared to $2,132,026, or $2.85 per share, for the same period in 2024[280] - Comprehensive loss for the three months ended June 30, 2025, was $13,458,494, compared to $2,129,320 for the same period in 2024[283] Cash Flow and Working Capital - The company incurred a working capital deficit of approximately $14,132,000 as of June 30, 2025[252] - The company generated negative cash flow from operating activities of approximately $3,028,000 for the six months ended June 30, 2025[252] - As of June 30, 2025, the company's cash balance was approximately $201,532, a decrease of 92.9% from $2,856,309 on December 31, 2024[286] - The working capital deficit increased by $3,486,262 to $14,132,319 at June 30, 2025, primarily due to a decrease in cash and increases in accrued liabilities[286] - Net cash used in operating activities for the six months ended June 30, 2025 was $3,027,822, reflecting a consolidated net loss of approximately $15,941,000[289] - The company reported a net cash flow provided by financing activities of $277,636 for the six months ended June 30, 2025, a significant decrease from $2,010,577 in the same period of 2024[292] - The company expects cash used in operating activities to increase in the next 12 months due to rising operational costs and working capital requirements[291] Assets and Liabilities - The total current assets decreased by 71.2% from $3,236,498 on December 31, 2024 to $933,088 on June 30, 2025[286] - The total current liabilities increased by 8.5% from $13,882,555 on December 31, 2024 to $15,065,407 on June 30, 2025[286] Business Operations and Strategy - The company has suspended all research and development efforts related to cellular therapy to focus on product commercialization[250] - The company plans to target the diabetes and obesity markets with the KetoAir breathalyzer device[246] - The KetoAir device is registered as a Class I medical device with the U.S. FDA and is paired with an "AI Nutritionist" software program[248] - The company has ceased all operations in China since 2022, limiting future revenue generation from that market[296] - The company will need to raise significant additional capital to fund operations and provide working capital, with no assurance that financing will be available on acceptable terms[295] Financial Viability - The company has a limited operating history and its continued growth is dependent on generating rental revenue and obtaining additional financing, raising substantial doubt about its ability to continue as a going concern[285]

Core Viewpoint - Avalon GloboCare Corp. has announced a wholesale distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device, aimed at first responders as part of Saga's Holistic Health Reset Program [1][3]. Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and cellular therapy intellectual property [5]. - The company is currently marketing the KetoAir™ breathalyzer, which is registered as a Class I medical device with the U.S. FDA [5]. - Avalon also focuses on advancing its intellectual property portfolio through existing patent applications and operates commercial real estate [5]. Product Details - The KetoAir™ breathalyzer is designed for ketogenic health management, measuring breath acetone concentration (BrAce) to indicate fat metabolism and ketosis [2]. - It is intended for users on ketogenic diets for weight loss, athletic performance, or therapeutic purposes, utilizing nano-sensor technology for real-time insights [2]. - The device is compatible with both Apple and Android devices and is available on the Apple App Store and Google Play Store [2]. Partnership Significance - The agreement with Saga Health is seen as a milestone for accelerating the commercial expansion of the KetoAir™ device [3]. - The collaboration aims to meet the growing demand for personalized, real-time monitoring of BrAce among those pursuing ketogenic lifestyles [3]. - Saga Health's Holistic Health Reset Program provides personalized nutritional guidance and tools like the KetoAir™ breathalyzer to improve participants' health [6].

Core Points - Avalon GloboCare Corp. announced the issuance of a new standard patent for its CAR-T and CAR-Natural Killer (NK) cell technology in Hong Kong, marking a significant milestone in its global intellectual property strategy [1][2][3] - The patent, effective from February 21, 2020, provides 20 years of protection for the company's proprietary technology, reinforcing its competitive position in the field of cell-based immunotherapy [2][3] - The patented technology aims to enhance the manufacturing, expansion, survival, and therapeutic efficacy of CAR-T and CAR-NK cells, which is crucial for advancing treatment options in hematologic malignancies [3][7] Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, including the marketing of the KetoAir™ breathalyzer device [4] - The company is also engaged in the development of additional diagnostic uses for its breathalyzer technology, which is registered as a Class I medical device with the U.S. FDA [4] - Avalon continues to expand its intellectual property portfolio through existing patent applications and also owns and operates commercial real estate [4]

Core Viewpoint - Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer aimed at enhancing public safety and supporting real-time detection of cannabis-impaired driving [1][2][3] Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and is advancing intellectual property in cellular therapy [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device [4] Strategic Collaboration - The collaboration involves Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics to jointly design, validate, and develop a prototype for the cannabis breathalyzer device [2] - This partnership aims to combine Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to create a non-invasive cannabis detection solution [3] Public Health Impact - The cannabis breathalyzer is intended to support law enforcement and workplace safety by providing a real-time detection solution for cannabis impairment [3]

Core Viewpoint - Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics Limited to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer aimed at enhancing public safety and supporting real-time detection of cannabis-impaired driving [1][2][3] Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and is advancing intellectual property in cellular therapy [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device [4] Strategic Collaboration - The collaboration involves Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics to jointly design, validate, and develop a prototype for the cannabis breathalyzer device [2] - This partnership aims to combine Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to provide a non-invasive cannabis detection solution [3]

[Part I – Financial Information](index=3&type=section&id=Part%20I%20%E2%80%93%20Financial%20Information) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) Q1 2025 net loss was $2.48 million, total assets decreased to $10.6 million, and a $11.7 million working capital deficit raises substantial doubt about going concern [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased by 49.4% to $10.6 million as of March 31, 2025, primarily due to the disposition of equity method investments, resulting in a $3.9 million equity deficit Condensed Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Item | March 31, 2025 ($) | December 31, 2024 ($) | Change (%) | | :--- | :--- | :--- | :--- | | **Total Assets** | **10,609,789** | **20,985,178** | **-49.4%** | | Cash | 1,369,586 | 2,856,309 | -52.0% | | Equity method investments, net | - | 10,636,544 | -100.0% | | **Total Liabilities** | **14,501,059** | **13,882,555** | **+4.5%** | | Total Current Liabilities | 14,449,353 | 13,882,555 | +4.1% | | **Total (Deficit) Equity** | **(3,891,270)** | **7,102,623** | **-154.8%** | | Accumulated deficit | (90,155,236) | (87,673,125) | +2.8% | - The company disposed of its 40% equity interest in Lab Services MSO during the first quarter of 2025, resulting in the elimination of the 'Equity method investments' asset from the balance sheet[9](index=9&type=chunk)[27](index=27&type=chunk)[54](index=54&type=chunk) [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss for Q1 2025 increased to $2.48 million from $1.37 million in Q1 2024, primarily due to a significant rise in professional fees Consolidated Statement of Operations Highlights (Unaudited, For the Three Months Ended March 31) | P&L Item | 2025 ($) | 2024 ($) | Change (%) | | :--- | :--- | :--- | :--- | | Real Property Rental Revenue | 349,800 | 314,588 | +11.2% | | Income from Equity Method Investment | 392,677 | 107,469 | +265.4% | | Total Other Operating Expenses | 2,268,862 | 1,001,993 | +126.4% | | - Professional fees | 1,691,579 | 442,335 | +282.4% | | Loss from Operations | (1,806,775) | (843,062) | +114.3% | | **Net Loss** | **(2,482,111)** | **(1,367,513)** | **+81.5%** | | **Net Loss per Share (Basic & Diluted)** | **(1.43)** | **(1.86)** | **-23.1%** | [Condensed Consolidated Statements of Changes in (Deficit) Equity](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20(Deficit)%20Equity) Total equity shifted from $7.1 million positive to a $3.9 million deficit due to net loss and preferred stock changes - Series B Convertible Preferred Stock with a carrying value of **$11,000,000** was extinguished as part of the consideration for the redemption of the company's investment in Lab Services MSO[14](index=14&type=chunk)[170](index=170&type=chunk) - **9,000 shares** of Series A Convertible Preferred Stock (**$9,000,000** carrying value) were exchanged for **5,000 shares** of newly created Series D Convertible Preferred Stock[14](index=14&type=chunk)[167](index=167&type=chunk) - The net loss for the quarter was **$2,482,111**, which directly reduced the accumulated deficit[14](index=14&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations increased to $1.8 million in Q1 2025, leading to a $1.49 million cash decrease to $1.37 million Consolidated Cash Flow Highlights (Unaudited, For the Three Months Ended March 31) | Cash Flow Item | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Net Cash Used in Operating Activities | (1,801,926) | (915,709) | | Net Cash Provided by Investing Activities | 95,000 | - | | Net Cash Provided by Financing Activities | 219,972 | 936,772 | | **Net (Decrease) Increase in Cash** | **(1,486,723)** | **20,068** | | **Cash - End of Period** | **1,369,586** | **305,468** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail KetoAir focus, lab services cessation, a $11.7 million working capital deficit, and ongoing litigation settlement obligations - The company is a commercial-stage company focused on developing and delivering precision diagnostic consumer products, primarily the **KetoAir™** breathalyzer device, and owns income-producing real estate[23](index=23&type=chunk)[25](index=25&type=chunk) - On February 26, 2025, the company's **40% equity interest** in Lab Services MSO was redeemed, effectively ending its laboratory testing services segment, with the company receiving **$1.745 million** in cash consideration (payable over time) and all of its Series B Preferred Stock surrendered[27](index=27&type=chunk)[54](index=54&type=chunk)[170](index=170&type=chunk) - The company had a working capital deficit of approximately **$11.7 million** and recurring net losses, which raises substantial doubt about its ability to continue as a going concern, with its continuation dependent on raising additional capital[37](index=37&type=chunk)[38](index=38&type=chunk) - On January 9, 2025, the company's chairman exchanged **9,000 shares** of Series A Preferred Stock for **5,000 shares** of new Series D Preferred Stock[124](index=124&type=chunk)[137](index=137&type=chunk)[167](index=167&type=chunk) - The company has an outstanding litigation settlement obligation with accrued payments of **$373,450** as of March 31, 2025[202](index=202&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses KetoAir, Q1 2025 net loss of $2.5 million from professional fees, and going concern doubts due to a $11.7 million working capital deficit - The company's primary focus is on commercializing the **KetoAir™** breathalyzer device and developing its intellectual property through a partnership with MIT[214](index=214&type=chunk)[215](index=215&type=chunk)[217](index=217&type=chunk) - To preserve cash, the company sold its **40% interest** in Lab Services MSO on February 26, 2025, and has suspended R&D efforts related to cellular therapy[220](index=220&type=chunk)[221](index=221&type=chunk) - A significant increase in professional fees of **$1.25 million** was mainly due to consulting and legal services for a potential merger with YOOV Group Holding Limited[241](index=241&type=chunk) - Management explicitly states that there is substantial doubt about the company's ability to continue as a going concern due to a working capital deficit of **$11.7 million**, recurring losses, and a cash balance insufficient for the next 12 months[224](index=224&type=chunk)[225](index=225&type=chunk)[251](index=251&type=chunk) Key Operational Results (For the Three Months Ended March 31) | Metric | 2025 ($) | 2024 ($) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Real Property Rental Revenue | 349,800 | 314,588 | +11.2% | Increase in number of tenants | | Loss from Operations | (1,806,775) | (843,062) | +114.3% | Primarily due to higher professional fees | | Net Loss | (2,482,111) | (1,367,513) | +81.5% | Increased operating loss and other expenses | [Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Avalon GloboCare Corp. is not required to provide the information for this item - The company is exempt from this disclosure requirement because it qualifies as a smaller reporting company[263](index=263&type=chunk) [Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) Management evaluated the company's disclosure controls and procedures as of March 31, 2025, and concluded they were not effective due to un-remediated material weaknesses previously identified in the 2024 Annual Report on Form 10-K - Management concluded that disclosure controls and procedures were not effective as of March 31, 2025[266](index=266&type=chunk) - The ineffectiveness is due to material weaknesses previously reported in the Form 10-K for the year ended December 31, 2024, which have not yet been remediated[266](index=266&type=chunk) - There were no changes in internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, internal controls[267](index=267&type=chunk) [Part II – Other Information](index=43&type=section&id=Part%20II%20%E2%80%93%20Other%20Information) [Legal Proceedings](index=43&type=section&id=Item%201.%20Legal%20Proceedings) The company is subject to a 2019 lawsuit settlement requiring fixed and contingent payments, with $373,450 accrued as of March 31, 2025 - The company is party to a settlement agreement stemming from a 2019 lawsuit involving allegations of trade secret misappropriation against its subsidiary Genexosome and former Co-CEO Dr. Zhou[270](index=270&type=chunk) - The settlement terms include fixed payments and future profit-sharing arrangements with the Research Institute[270](index=270&type=chunk) [Risk Factors](index=43&type=section&id=Item%201A.%20Risk%20Factors) The company, as a smaller reporting company, is not required to disclose material changes to its risk factors in the 10-Q, referring investors to its Annual Report on Form 10-K - The company directs investors to its most recent Form 10-K for a comprehensive discussion of risk factors[271](index=271&type=chunk) - As a smaller reporting company, disclosure of material changes to risk factors in the quarterly report is not required[272](index=272&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Q1 2025 saw the issuance of 22,278 common shares for services and 186,877 shares from cashless warrant exercises, all exempt from registration - Issued **22,278 common shares** for services rendered and to be rendered, valued at **$111,232**[274](index=274&type=chunk) - Issued **186,877 common shares** upon the cashless exercise of outstanding warrants[275](index=275&type=chunk) [Other Information](index=44&type=section&id=Item%205.%20Other%20Information) The company reported no material information under this item for the quarter, and confirmed no material changes to board nominee procedures or Rule 10b5-1 trading plans - No material information was reported under Item 5(a)[279](index=279&type=chunk) - No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during the quarter ended March 31, 2025[280](index=280&type=chunk) [Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section lists all Form 10-Q exhibits, including the YOOV Group Holding merger agreement, redemption agreement, and officer certifications - Key exhibits filed include the merger agreement with YOOV Group Holding, the redemption agreement for the Lab Services MSO investment, and certifications by the CEO and CFO[284](index=284&type=chunk)

Core Viewpoint - Avalon GloboCare Corp. and YOOV Group Holding Limited have announced a proposed merger, aiming to create a publicly-traded company focused on AI-driven business automation solutions [1][2]. Company Overview - Avalon GloboCare Corp. is a commercial-stage company specializing in precision diagnostic consumer products and cellular therapy, currently marketing the KetoAir™ breathalyzer device, which is registered as a Class I medical device with the U.S. FDA [6]. - YOOV Group Holding Limited is an AI-as-a-Service platform that specializes in intelligent business automation, allowing businesses to optimize operations without extensive resources or technical expertise [4]. Merger Details - The merger involves Nexus MergerSub Limited, a wholly owned subsidiary of Avalon, merging with YOOV, with YOOV becoming a wholly owned subsidiary of Avalon [2]. - The merger is subject to stockholder approval from Avalon and the Nasdaq Stock Market's approval for YOOV's listing post-merger [3]. Additional Offerings - YOOV extends its services into financial and insurance sectors through subsidiaries YOOV Capital Limited and YOOV Insurance Services Limited, enhancing its ecosystem with credit evaluation and insurance brokerage services [5].

Core Insights - Avalon GloboCare Corp. has partnered with SpecialtyHealth, Inc. to enhance its BrAce 4 Impact Challenge, integrating SpecialtyHealth into its Zero to Keto Affiliate Marketing Program [1][6] - The KetoAir™ breathalyzer is being utilized by law enforcement as a motivational tool to support health and wellness initiatives [2][3] - The collaboration aims to promote healthier habits among first responders by managing ketone levels through the use of the KetoAir™ device [4][6] Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy [8] - The company is currently marketing the KetoAir™ breathalyzer, which is registered as a Class I medical device with the U.S. Food and Drug Administration [6][8] - Avalon also operates in the commercial real estate sector, indicating a diversified business model [8] Product Details - The KetoAir™ breathalyzer measures breath acetone concentration, providing real-time insights into an individual's ketosis status [6] - The device is designed for ease of use, fitting into a uniform pocket for convenient monitoring by law enforcement officers [3] - The technology behind KetoAir™ leverages nano-sensor capabilities to assess ketone levels, supporting users in their weight management efforts [6]